Impacto dos agonistas do receptor do peptídeo 1 semelhante ao glucagon na prevenção de eventos cardiovasculares maiores em pacientes com diabetes mellitus tipo 2: protocolo de revisão de escopo

This scoping review will aim to map and synthesize the available scientific evidence on the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the prevention of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus (T2DM). The review will be conducted in accordance with the methodological recommendations of the Joanna Briggs Institute (JBI) and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). The research question will be formulated using the Population, Concept, and Context (PCC) framework. Searches will be performed in MEDLINE/PubMed, the Virtual Health Library (VHL), and the Cochrane Library. Eligible publications will include primary studies, systematic reviews, clinical practice guidelines, and consensus documents addressing cardiovascular outcomes associated with GLP-1 RA therapy. Two independent reviewers will screen titles, abstracts, and full texts according to predefined eligibility criteria, with disagreements resolved through consensus or consultation with a third reviewer. Data will be extracted using a standardized instrument and synthesized descriptively to characterize the therapeutic interventions, cardiovascular outcomes, clinical applicability, and existing knowledge gaps. The review is expected to provide a comprehensive overview of the evidence regarding the cardiovascular benefits of GLP-1 RAs, supporting evidence-based clinical decision-making and identifying priorities for future research.